Welcome to Optimal - The Biomarkers where we cover new and interesting information and research on the biomarkers that we analyze and interet in the Optimal DX Software Application.
Today's audio presentation covers 2 important Functional Medicine ratios: the ALT:AST Ratio and the AST:ALT Ratio and finishes up with a discussion on Ceruloplasmin
Here's a breakdown of what we covered and timing:
Sg, R., Dhamija, R., Gurtoo, A., & Singh, R. (2017). Correlation Of Alt/ast Ratio With Insulin Resistance In Metabolic Syndrome. International Journal of Advanced Research, 5(3), 1677-1684. [R]
Botros M, Sikaris KA. The de ritis ratio: the test of time. Clin Biochem Rev. 2013 Nov;34(3):117-30. [R]
Hanley AJ, Williams K, Festa A, et al. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes. 2005 Nov;54(11):3140-7. [R]
Tang WH, Wu Y, Hartiala J, et al. Clinical and genetic association of serum ceruloplasmin with cardiovascular risk. Arterioscler Thromb Vasc Biol. 2012 Feb;32(2):516-22. [R]
Hammadah M, Fan Y, Wu Y, et al. Prognostic value of elevated serum ceruloplasmin levels in patients with heart failure. J Card Fail. 2014 Dec;20(12):946-52. [R]
Mak CM, Lam CW, Tam S. Diagnostic accuracy of serum ceruloplasmin in Wilson disease: determination of sensitivity and specificity by ROC curve analysis among ATP7B-genotyped subjects. Clin Chem. 2008 Aug;54(8):1356-62. [R]
Xu R, Jiang YF, Zhang YH, et al. The optimal threshold of serum ceruloplasmin in the diagnosis of Wilson's disease: A large hospital-based study. PLoS One. 2018 Jan 11;13(1):e0190887 [R]